These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32233241)

  • 1. [PDE5 inhibitors as a medicinal guide drug in the treatment of erectile dysfunction].
    Chen Y; Zhang J
    Zhonghua Nan Ke Xue; 2019 Nov; 25(11):1040-1044. PubMed ID: 32233241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Yan H; Zong H; Cui Y; Li N; Zhang Y
    J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Update of PDE5 inhibitors for the treatment of ischemia-reperfusion].
    Hu YY; Wu ZG
    Zhonghua Nan Ke Xue; 2011 Sep; 17(9):842-6. PubMed ID: 21961251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
    Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
    J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
    Cui Y; Liu X; Shi L; Gao Z
    Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation.
    Scaglione F; Donde S; Hassan TA; Jannini EA
    Clin Ther; 2017 Feb; 39(2):370-377. PubMed ID: 28139291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicinal plants as a potential source of Phosphodiesterase-5 inhibitors: A review.
    Anand Ganapathy A; Hari Priya VM; Kumaran A
    J Ethnopharmacol; 2021 Mar; 267():113536. PubMed ID: 33137431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDE5 inhibitors: targeting erectile dysfunction in diabetics.
    Francis SH; Corbin JD
    Curr Opin Pharmacol; 2011 Dec; 11(6):683-8. PubMed ID: 21924956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the association between erectile rigidity and treatment adherence with sildenafil.
    Mazzola CR; Deveci S; Teloken P; Mulhall JP
    J Sex Med; 2013 Jul; 10(7):1861-6. PubMed ID: 23253943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of erectile dysfunction course on its progress and efficacy of treatment with phosphodiesterase type 5 inhibitors.
    Liu DF; Jiang H; Hong K; Zhao LM; Tang WH; Ma LL
    Chin Med J (Engl); 2010 Nov; 123(22):3258-61. PubMed ID: 21163126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avanafil for erectile dysfunction.
    Kyle JA; Brown DA; Hill JK
    Ann Pharmacother; 2013 Oct; 47(10):1312-20. PubMed ID: 24259695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients with end-stage renal disease receiving dialysis or after renal transplantation.
    Lasaponara F; Sedigh O; Pasquale G; Bosio A; Rolle L; Ceruti C; Timpano M; Negro CL; Paradiso M; Abbona A; Segoloni GP; Fontana D
    J Sex Med; 2013 Nov; 10(11):2798-814. PubMed ID: 23346948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of psychological intervention and phosphodiesterase-5 inhibitors for erectile dysfunction: a narrative review and meta-analysis.
    Schmidt HM; Munder T; Gerger H; Frühauf S; Barth J
    J Sex Med; 2014 Jun; 11(6):1376-91. PubMed ID: 24641632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of short- and long-term, regular and on-demand regimens of phosphodiesterase type 5 inhibitors in treating erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis.
    Tian D; Wang XY; Zong HT; Zhang Y
    Clin Interv Aging; 2017; 12():405-412. PubMed ID: 28260869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
    Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
    J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
    Gacci M; Andersson KE; Chapple C; Maggi M; Mirone V; Oelke M; Porst H; Roehrborn C; Stief C; Giuliano F
    Eur Urol; 2016 Jul; 70(1):124-133. PubMed ID: 26806655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.
    Ioakeimidis N; Kostis JB
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):53-64. PubMed ID: 24281316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vardenafil improves penile erection in type 2 diabetes mellitus patients with erectile dysfunction: role of tropomyosin.
    Zamorano-León JJ; Olivier C; de Las Heras N; Mateos-Cáceres PJ; Brime Menéndez R; Rodríguez-Sierra P; Martín Palacios N; Manso LS; Modrego J; Segura A; Macaya C; López-Farré AJ
    J Sex Med; 2013 Dec; 10(12):3110-20. PubMed ID: 24112450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors.
    Sung HH; Ahn JS; Kim JJ; Choo SH; Han DH; Lee SW
    Andrology; 2014 Jan; 2(1):45-50. PubMed ID: 24194017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment effects of phosphodiesterase-5 inhibitors may improve with time following nerve-sparing radical prostatectomy.
    Fode M; Østergren PB; Jensen CFS; Jakobsen H; Sønksen J
    Scand J Urol; 2018 Apr; 52(2):108-110. PubMed ID: 29057723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.